肾透明细胞癌的更新（致敬翁德雷·赫斯教授）
Updating Clear Cell Renal Cell Carcinoma (a Tribute to Prof. Ondrej Hes).
作者信息
Manini Claudia, López José I
机构信息
Department of Pathology, San Giovanni Bosco Hospital, 10154 Turin, Italy.
Department of Sciences of Public Health and Pediatrics, University of Turin, 10124 Turin, Italy.
出版信息
Cancers (Basel). 2022 Aug 18;14(16):3990. doi: 10.3390/cancers14163990.
Abstract
This Special Issue provides an insight into critical issues concerning clear cell renal cell carcinomas (CCRCCs), reflecting the recent level of intricacy reached by renal oncology [...].
摘要
本期特刊深入探讨了与透明细胞肾细胞癌（CCRCC）相关的关键问题，反映了肾肿瘤学目前达到的复杂程度[……]。
相似文献
1
Updating Clear Cell Renal Cell Carcinoma (a Tribute to Prof. Ondrej Hes).肾透明细胞癌的更新（致敬翁德雷·赫斯教授）
Cancers (Basel). 2022 Aug 18;14(16):3990. doi: 10.3390/cancers14163990.
2
A tribute to Prof. Ondrej Hes, MD, PhD (1968-2022).向翁德雷·赫斯教授致敬，医学博士、哲学博士（1968 - 2022）。
Mod Pathol. 2022 Dec;35(12):2023-2024. doi: 10.1038/s41379-022-01159-8.
3
Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.多期多层计算机断层扫描在鉴别高碳酸酐酶-IX 表达和低碳酸酐酶-IX 表达的透明细胞肾细胞癌中的应用。
Abdom Radiol (NY). 2018 Oct;43(10):2734-2742. doi: 10.1007/s00261-018-1546-8.
4
[Role of multiphasic multidetector CT imaging in differential diagnosis of small renal cell carcinoma].[多期多层螺旋CT成像在小肾癌鉴别诊断中的作用]
Zhonghua Zhong Liu Za Zhi. 2015 Nov;37(11):850-4.
5
The utility of using immunohistochemistry in the differentiation of metastatic, cutaneous clear cell renal cell carcinoma and clear cell hidradenoma.免疫组织化学在转移性皮肤透明细胞肾细胞癌和透明细胞汗腺瘤鉴别诊断中的应用。
J Cutan Pathol. 2017 Jul;44(7):612-615. doi: 10.1111/cup.12946. Epub 2017 May 16.
6
A large-scale transcriptome analysis identified ELANE and PRTN3 as novel methylation prognostic signatures for clear cell renal cell carcinoma.一项大规模的转录组分析确定 ELANE 和 PRTN3 为透明细胞肾细胞癌的新型甲基化预后标志物。
J Cell Physiol. 2020 Mar;235(3):2582-2589. doi: 10.1002/jcp.29162. Epub 2019 Sep 6.
7
Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas.CD44、基质金属蛋白酶 2 和基质金属蛋白酶 9 在肾细胞癌中的免疫组织化学表达。
Urol Oncol. 2019 Oct;37(10):742-748. doi: 10.1016/j.urolonc.2019.04.017. Epub 2019 Apr 30.
8
Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.受体酪氨酸激酶在人肾透明细胞癌中的激活和功能。
BMC Cancer. 2019 Nov 5;19(1):1044. doi: 10.1186/s12885-019-6159-2.
9
Value of intravoxel incoherent motion for differential diagnosis of renal tumors.体素内不相干运动在肾肿瘤鉴别诊断中的价值
Acta Radiol. 2019 Mar;60(3):382-387. doi: 10.1177/0284185118778884. Epub 2018 Jun 4.
10
Texture analysis and machine learning algorithms accurately predict histologic grade in small (< 4 cm) clear cell renal cell carcinomas: a pilot study.纹理分析和机器学习算法可准确预测小（<4cm）透明细胞肾细胞癌的组织学分级：一项初步研究。
Abdom Radiol (NY). 2020 Mar;45(3):789-798. doi: 10.1007/s00261-019-02336-1.
引用本文的文献
1
CDKN2A promoter methylation enhances self-renewal of glioblastoma stem cells and confers resistance to carmustine.CDKN2A 启动子甲基化增强胶质母细胞瘤干细胞的自我更新能力，并赋予其对卡莫司汀的耐药性。
Mol Biol Rep. 2024 Mar 5;51(1):385. doi: 10.1007/s11033-024-09247-5.
本文引用的文献
1
Prognostic Gene Expression-Based Signature in Clear-Cell Renal Cell Carcinoma.基于预后基因表达的透明细胞肾细胞癌特征
Cancers (Basel). 2022 Aug 1;14(15):3754. doi: 10.3390/cancers14153754.
2
Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas.迈向透明细胞肾细胞癌的个性化采样
Cancers (Basel). 2022 Jul 12;14(14):3381. doi: 10.3390/cancers14143381.
3
Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.基于基因组和转录组特征的分子亚型与转移性透明细胞肾细胞癌对免疫检查点抑制剂的反应性相关。
Cancers (Basel). 2022 May 10;14(10):2354. doi: 10.3390/cancers14102354.
4
Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions.透明细胞肾细胞癌中的放射基因组学：现状与未来方向综述
Cancers (Basel). 2022 Apr 22;14(9):2085. doi: 10.3390/cancers14092085.
5
PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma.PBRM1免疫组化表达谱与透明细胞肾细胞癌的组织形态学特征及肿瘤血管的内皮表达相关。
Cancers (Basel). 2022 Feb 20;14(4):1062. doi: 10.3390/cancers14041062.
6
LiKidMiRs: A ddPCR-Based Panel of 4 Circulating miRNAs for Detection of Renal Cell Carcinoma.LiKidMiRs：用于检测肾细胞癌的基于数字PCR的4种循环微RNA检测组
Cancers (Basel). 2022 Feb 9;14(4):858. doi: 10.3390/cancers14040858.
7
A Comprehensive Commentary on the Multilocular Cystic Renal Neoplasm of Low Malignant Potential: A Urologist's Perspective.低恶性潜能多房性囊性肾肿瘤综合评述：泌尿外科医生视角
Cancers (Basel). 2022 Feb 6;14(3):831. doi: 10.3390/cancers14030831.
8
The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics-Definition, Current Advances, and Future Directions.透明细胞肾细胞癌管理中的下一次范式转变：放射基因组学——定义、当前进展及未来方向
Cancers (Basel). 2022 Feb 4;14(3):793. doi: 10.3390/cancers14030793.
9
Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy.局限性透明细胞肾细胞癌的预后因素及其在辅助治疗中的应用
Cancers (Basel). 2022 Jan 4;14(1):239. doi: 10.3390/cancers14010239.
10
Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌对免疫治疗和抗血管生成治疗耐药的分子机制
Cancers (Basel). 2021 Nov 28;13(23):5981. doi: 10.3390/cancers13235981.
Zotero 插件